These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 8093573

  • 1. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Falardeau P, DiPaolo T.
    Adv Neurol; 1993; 60():113-8. PubMed ID: 8093573
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ, Grondin R, Bédard PJ.
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [Abstract] [Full Text] [Related]

  • 4. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

  • 5. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK, Banerji T, Jenner P, Marsden CD.
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [Abstract] [Full Text] [Related]

  • 6. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L, Frohna PA, Joyce JN, Schneider JS.
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF, Sheng J.
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [Abstract] [Full Text] [Related]

  • 9. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.
    Gomez-Mancilla B, Boucher R, Gagnon C, Di Paolo T, Markstein R, Bédard PJ.
    Mov Disord; 1993 Apr; 8(2):144-50. PubMed ID: 8474480
    [Abstract] [Full Text] [Related]

  • 10. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
    Blanchet PJ, Gomez-Mancilla B, Bédard PJ.
    J Neural Transm Suppl; 1995 Apr; 45():103-12. PubMed ID: 8748615
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    Gomez-Mancilla B, Bédard PJ.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 15. The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys.
    Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, Stoof JC.
    Mov Disord; 1994 Nov; 9(6):664-72. PubMed ID: 7845408
    [Abstract] [Full Text] [Related]

  • 16. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN.
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [Abstract] [Full Text] [Related]

  • 17. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
    Calon F, Goulet M, Blanchet PJ, Martel JC, Piercey MF, Bédard PJ, Di Paolo T.
    Brain Res; 1995 May 22; 680(1-2):43-52. PubMed ID: 7663983
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N, Mizuta E, Yoshida O, Kuno S.
    J Pharmacol Exp Ther; 1998 Jul 22; 286(1):228-33. PubMed ID: 9655864
    [Abstract] [Full Text] [Related]

  • 19. Endogenous dopaminergic tone and dopamine agonist action.
    Treseder SA, Smith LA, Jenner P.
    Mov Disord; 2000 Sep 22; 15(5):804-12. PubMed ID: 11009183
    [Abstract] [Full Text] [Related]

  • 20. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.